<DOC>
	<DOCNO>NCT00527566</DOCNO>
	<brief_summary>The purpose study determine whether Mepolizumab ( monoclonal antibody interleukin-5 ) safe well-tolerated therapy allow steroid taper patient steroid-dependent Churg-Strauss Syndrome ( CSS ) .</brief_summary>
	<brief_title>Mepolizumab As Steroid-sparing Treatment Option Churg Strauss Syndrome</brief_title>
	<detailed_description>Specific Aims : 1 . Document safety mepolizumab therapy patient CSS . 2 . Demonstrate steroid spar effect mepolizumab therapy decrease corticosteroid dosage use anti-IL5 therapy . 3 . Demonstrate efficacy anti-IL5 therapy improve sign symptom CSS : 1 . Measuring serum marker CSS disease activity , include : peripheral eosinophilia , erythrocyte sedimentation rate , anti- neutrophil cytoplasmic antigen , C-reactive protein IgE level . 2 . Assessing activity level vasculitis via Birmingham Vasculitis Activity Score 3 . Evaluating asthmatic response via serial peak flow FEV1 measurement well asthma symptom score use Juniper scale . 4 . Assessing change novel parameter fractional excretion nitric oxide IL-5 level .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<criteria>Age &gt; 18 year old Diagnosis Churg Strauss Syndrome Maintained stable corticosteroid dose least prednisone 10mg daily ( equivalent ) prior enrollment study If cyclophosphamide , azathioprine methotrexate , must stable dose able maintain dose duration study Hypereosinophilic Syndrome Wegener 's Granulomatosis Malignancy Parasitic Disease Pregnant nursing If female childbearing potential , must negative pregnancy test prior infusion study medication must adhere acceptable method contraception ( &lt; 1 % failure rate ) Any medical illness precludes study involvement</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Churg Strauss Syndrome</keyword>
</DOC>